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to control patients (p  ! 0.001). No differences in the instabil-
ity score were observed between the groups. Furthermore, 
treated patients performed more ADL (p  ! 0.05).  Conclu-
sion: In the PLG-treated group, recovery was faster and pa-
tients returned earlier to daily activities and also took less 
pain medication than control subjects. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Open subacromial decompression (OSD) treatment 
for chronic impingement syndrome of the shoulder has 
been well documented  [1–3] . The space between the ac-
romion and humeral head is normally narrow and de-
creases with abduction of the arm. Any condition that 
further narrows this space can cause impingement of the 
shoulder top, the humeral head and the underlying soft 
tissue. Impingement can result from extrinsic compres-
sion or from rotator cuff insufficiency. Most common 
symptoms of shoulder impingement are pain, weakness 
and limitation in the range of motion.
 During and after OSD surgery, the patients own de-
fense mechanism is activated to reduce bleeding and ini-
tiate wound healing. Platelets play a pivotal role in this 
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 Abstract 
 Background: Platelet-leukocyte gel (PLG) is being used dur-
ing various surgical procedures in an attempt to enhance the 
healing process. We studied the effects of PLG on postop-
erative recovery of patients undergoing open subacromial 
decompression (OSD).  Methods: PLG was produced from 
platelet-leukocyte-rich plasma (P-LRP), prepared from a unit 
of whole blood. Forty patients were included in the study. 
Self-assessed evaluations, using the American Shoulder and 
Elbow Surgeons scoring system of activities of daily living 
(ADL), joint instability, pain levels, pain medications, and 
clinical evaluations for range of motion were conducted.  Re-
sults: Platelet and leukocyte counts were significantly in-
creased in the P-LRP compared to baseline counts. Treated 
patients demonstrated decreased visual analog scales for 
pain and used significantly less pain medication, had an im-
proved range of motion during passive forward elevation, 
external rotation, external rotation with arm at 90° abduc-
tion, internal rotation, and cross body adduction compared 
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process through the formation of a platelet plug and ac-
tivation of the blood coagulation cascade. Activated 
platelets at the wound site release several platelet growth 
factors, which initiate connective tissue healing and in-
crease mitogenesis, angiogenesis, and macrophage mi-
gration  [4, 5] . At present, autologous platelet-leukocyte 
gel (PLG) can be prepared safely from the patient’s own 
blood. A unit of whole blood, collected just prior to sur-
gery, is centrifuged to obtain platelet-leukocyte-rich plas-
ma (P-LRP). The PLG is then formed by mixing P-LRP 
with a thrombin-calcium chloride preparation  [6] . Treat-
ment with PLG provides a source of concentrated plate-
lets, with   -granules that contain platelet-derived growth 
factor (PDGF) and transforming growth factor (TGF)-  . 
These growth factors augment the wound healing pro-
cess  [7, 8] . The high concentration of non-activated leu-
kocytes, present in the PLG, promotes anti-microbial ac-
tivity at the wound site through destruction of bacteria 
and foreign materials and removal of damaged tissue  [9, 
10] .
 The success rate of an OSD depends on a rapid recov-
ery of the shoulder function. Time to recovery can be 
improved through good wound healing and less postop-
erative pain. This is the first prospective randomized, 
double-blind study in which autologous PLG has been 
used during OSD. The purpose of this study was to eval-
uate the effect of PLG on surgical wound healing with 
emphasis on the restoration of range of motion, activities 
of daily living (ADL), pain and pain medication, as part 
of the treatment of the impingement syndrome (Neer 
grade II) using the American Shoulder and Elbow Sur-
geons (ASES) shoulder assessment method to evaluate 
the study objectives  [11] .
 Patients and Methods 
 Study Design 
 The study was approved by the Institutional Ethics Commit-
tee of the Catharina Hospital, and a written informed consent was 
obtained from each patient according to the guidelines. Forty pa-
tients were prospectively entered into the study on the day of sur-
gery.
 Patient Identifiers and Randomization Procedure 
 Each patient received a unique patient identifier code. Formal 
randomization took place before the study started. Patients with 
patient codes corresponding to the drawn random numbers were 
assigned to the PLG treatment group, the other patients were as-
signed to the conventional treatment group. Investigators drew 
sealed envelopes with patient identifiers. Each envelope contained 
the randomization outcome for the identified patient. Study per-
sonnel opened the envelope within a time frame to guarantee that 
personnel were available to execute the PLG preparation and ap-
plication procedure.
 Patients were blinded with regard to which group they were 
randomized to prevent bias on answering pain sensation ques-
tions during the follow-up period and range of motion assess-
ment. Randomization information was not put in the patients 
medical or nurse files.
 The patients in the treatment group (n = 20) were injected with 
PLG, whereas the control group was not injected (n = 20). Patients 
were blinded with regard to which group they were randomized, 
to prevent bias when answering questions on pain sensation dur-
ing the follow-up period.
 Patients 
 The unique patient identifier codes enabled a reviewer to iden-
tify and compare the test results. The criteria for inclusion in the 
study were stage II impingement syndrome diagnosed more than 
6 months preoperatively. Patients had a history of typical anterior 
pain during shoulder elevation, marked loss of active and passive 
shoulder motion, loss of range of motion, and an initial positive 
response to three subacromial infiltrations performed in a 6-
month period with a local anesthetic and corticoids (xylocaine 
and methylprednisolone). Standard magnetic resonance imaging 
was used in all patients to assess glenohumeral and acromiocla-
vicular arthrosis, and measure subacromial calcifications. None 
of the patients had previous operative treatment. Furthermore, no 
patient showed evidence of a rotator cuff lesion on physical ex-
amination. However, if a rotator cuff lesion was observed during 
surgery, the patient was eliminated from the study. Exclusion cri-
teria were a history of frozen shoulder, disorders of the acromio-
clavicular joint, degenerative arthritis of the glenohumeral joint, 
and calcifying tendonitis, shoulder instability, posttraumatic dis-
orders, shoulder and elbow surgery, and hand disorders. None of 
the patients had accompanying diseases which would affect post-
operative wound healing (e.g. diabetes), or were treated for acute 
shoulder dysfunction. The postoperative examinations were per-
formed by an independent physician or nurse practitioner, blind-
ed to the peri-operative treatment to prevent bias during the 
shoulder function testing. The ASES scoring method was applied 
to evaluate patients before and after surgery. The ASES scoring 
system is used to assess the outcome of patients after OSD, and 
produces scores equivalent to those obtained with the Constant 
and University of California at Los Angeles shoulder scales  [12] . 
Furthermore, a psychometric analysis revealed that the ASES 
score is a reliable and valid responsive outcome tool  [13] .
 PLG Preparation Device 
 PLG was prepared with the Magellan TM Autologous Platelet 
Separator System (MAPS; Medtronic, Minneapolis, Minn., USA).
This device consists of a microprocessor-controlled centrifuge 
and two syringe pumps. One unit of blood is drawn from each 
patient, and is then pumped into the MAPS separation chamber. 
The blood sample is centrifuged at 1,200  g , separating erythro-
cytes from the plasma. The low-density platelets separate and can 
be found between the red blood cells and the plasma. During cen-
trifugation the syringe starts with the collection of the erythro-
cytes. When the light sensor in the MAPS detects the low-density 
platelets at the outer ends of the chamber, a second syringe col-
lects the P-LRP.
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 PLG Preparation 
 Blood for the PLG preparation was drawn after induction of 
anesthesia from all patients in the treatment group and the con-
trol group to guarantee patient blinding. In patients randomized 
to the PLG group, a total of 104 ml of whole blood was slowly 
drawn in two 60-ml syringes. Each syringe contained 52 ml of 
blood and 8 ml of the anticoagulant citrate dextrose solution-A to 
prevent clotting prior to the preparation of P-LRP. The MAPS was 
set to deliver 8 ml of P-LRP after each cycle. A total volume of 16 
ml of P-LRP was distributed into three aliquots: 0.5 ml of P-LRP 
was used to determine platelet and leukocyte counts; 3.5 ml of P-
LRP was used to prepare autologous thrombin for activating the 
P-LRP to produce PLG; the remaining 12 ml of P-LRP was used 
to prepare PLG.
 Surgical Technique 
 All patients were placed in the beach-chair position, and oper-
ated on by two surgeons well experienced in OSD surgery. OSD 
was performed via a 4-cm shoulder strap skin incision, centered 
over the acromial clavicular joint. A deltoid splitting incision was 
made with electrocautery. The deltoid fibers were subperiostially 
released from the anterior acromion to facilitate exposure. A stan-
dard anterior acromioplasty was performed were the anterolat-
eral and central portion of the subacromial bone were resected, 
using an oscillating saw. The decompression was completed when 
the acromion was considered flat. All osteophytes were removed 
from the undersurface. Prior to wound closure, the cuff was in-
spected for tears. The deltoid was re-attached with absorbable su-
tures. The subcutaneous layer was closed with an absorbable run-
ning suture and the skin was closed with a subcuticular suture. 
No drains were used in either patient group in order to avoid 
draining the PLG growth factors from the wound site. 
 Upon discharge, all patients had an arm sling for support of 
their operated arm. Postoperatively, all patients were treated ac-
cording to a standard rehabilitation protocol, starting with active 
assisted range of motion on day 1. As pain decreased, this pro-
gressed with strengthening exercises of the rotator cuff and shoul-
der muscles. Formal physical therapy, including standard pulley 
exercises, was started in the 2nd postoperative week and contin-
ued until full range of motion returned. After achieving full range 
of motion, patients could either choose to continue physical ther-
apy or begin a strengthening program at home.
 PLG Application 
 In the PLG treatment group, a blunt 14-gauge needle was 
placed identically in all patients in the subacromial space during 
wound closure. After closure of the deltoid layer and the subcuta-
neous tissue, an intracapsular injection of 10 ml of PLG was given. 
Before skin closure, an additional 3 ml of PLG were injected under 
the subcutaneous layer covering the incision length. PLG was 
only given after the capsula and subcutaneous layers had been 
closed in order to avoid leakage of PLG outside the wound area 
( fig. 1 ). 
 Outcome Assessment 
 Data on the preoperative shoulder function were recorded. 
The ASES shoulder function assessment method is used to assess 
the ability to perform ADL, and includes a patient self-evaluation 
form and a physician assessment score to determine shoulder 
function including range of motion. The patient self-evaluation 
section contained visual analog scales for pain (VAS) on a ten-
point scale. Ten ADL were assessed on a four-point ordinal scale. 
Patients were requested to keep a journal from the 1st postopera-
tive week until 6 weeks after surgery to subjectively score symp-
toms, function, and ADL. Pain medication, instability, and an 
ADL questionnaire ( table 1 ) were completed in the absence of a 
physician. Pain medication was recorded as either regular (e.g. 
aspirin or ibuprofen) or strong (e.g. codeine or naproxen). The 
shoulder index score (SIS) was calculated from data obtained 
from the ADL form and VAS assessment. Time to recovery of 
shoulder function was assessed with the interval until resump-
tion of work, time until improvement in symptoms and ADL. The 
improvement in range of motion was assessed by an investigator 
who was blinded to the treatment given. A goniometer was used 
 Fig. 1. Illustration of PLG application through the incision line 
following OSD. After closure of the deltoid layer and the subcu-
taneous tissue, an intracapsular injection of 10 ml of PLG was 
given. 
Table 1. Items in the ASES patient self-assessment scale for ADL
1 Put on a coat
2 Sleep on painful or affected side
3 Wash back
4 Manage toileting
5 Comb hair
6 Reach a high self
7 Lift 5 kg above affected shoulder
8 Throw a ball overhand with affected shoulder
9 Do usual work
10 Do usual sport
Scores for items are: 0 = Unable to do; 1 = very difficult to do; 
2 = somewhat difficult; 3 = not difficult.
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to determine passive and active range of motion, which was de-
fined as forward elevation, external rotation, external rotation 
with arm at 90° abduction, internal rotation noting the highest 
point of the spinal anatomy, and cross body adduction. The pa-
tient was asked to identify whether he or she experienced symp-
toms of instability. The sensation of instability was assessed quan-
titatively according to a VAS. A higher score was given when the 
shoulder felt very unstable.
 Statistical Methods 
 Study data were collected on customized case report forms 
and entered into a computerized database that allowed unbiased 
and reliable data management. Statistical analysis utilized SAS  
statistical software (SAS Institute, Cary, N.C., USA, 2003). Cate-
gorical data were expressed as percentages with all 40 patients 
included. Measured data were expressed as means  8 SD.
 Univariate analysis was performed by means of Fisher’s exact 
test on all categorical data and Student’s t test on all measured 
data. Differences between means were analyzed using Student’s t 
test and Satterthwaite’s approximation which does not assume 
equal variances and provides a more conservative test of signifi-
cance than the standard t test  [14] . A two-sided p  ^  0.05 was con-
sidered to be statistically significant.
 Results 
 The baseline characteristics for the two groups are 
shown in  table 2 . The groups showed a similar distribu-
tion for age and gender, and there were no differences in 
the duration of symptoms prior to surgery. Also impor-
tant, the preoperative findings of VAS scores, functional 
range of motion, and SIS were similar among the two 
groups. All surgical procedures were uneventful, with no 
peri- or postoperative complications, and none of the pa-
tients received antibiotic treatment for infection. All pa-
tient self-assessment forms were returned to the investi-
gator and all patients completed the follow-up period.
 Platelet and Leukocyte Counts 
 Platelet and leukocyte counts were assessed with a ful-
ly automated analyzer (Cell-Dyn TM 4000, Abbott Diag-
nostics, Santa Clara, Calif., USA), using a combination of 
optical and impedance methods for all blood samples. 
The preoperative whole blood platelet count of PLG-
treated patients after MAPS centrifugation increased 
from 206  8 42 to 1,183  8 396  ! 10 9 /l in the P-LRP, a 
5.7-fold increase from baseline (p  ! 0.001). The preopera-
tive leukocyte count increased 2.7-fold compared to the 
leukocyte count in the P-LRP (4.8  8 1.3 and 13.0  8 2.8, 
respectively; p  ! 0.001).
 Pain and SIS 
 In the PLG-treated patients, a decrease in the VAS 
pain score was observed compared to the non-treated pa-
tients (p  ! 0.001;  fig. 2 ). After 3 months of follow-up, pain 
decreased markedly in both groups. The PLG-treated pa-
tients used significantly less pain medication, with only 
Table 2. Characteristics of the patients treated with OSD
Characteristics Control
(n = 20)
PLG
(n = 20)
Age, years 50814 52811
Females/males 10/5 8/7
Right/left 12/3 12/3
Dominant/non-dominant side 9/6 10/5
Working/sedentary 11/4 13/2
SIS (100 maximally), % 37818 39814
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Table 3. Use of pain medication after OSD 
Control (n = 20) PLG (n = 20)
regular/
strong
mean
(range)
regular/
strong
mean
(range)
Preoperatively 6/3 1.8 (0–6) 5/2 1.2 (0–5)
Postoperatively
1 week 5/5 2.7 (0–6) 5/0* 3.1 (0–6)
2 weeks 8/2 1.6 (0–6) 1/0* 0*
4 weeks 2/2 0.5 (0–2) 1/0* 0*
6 weeks 2/1 0.4 (0–2) 0 0
The patients were asked to identify the number of pills they 
took each day for pain medication, and whether they had taken a 
regular or strong analgesic. * p < 0.001 vs. the control group. Fig. 2. VAS pain score until 6 weeks postoperatively for the control 
( ––––– ) and PLG-treated patients (– – –).  * p  ! 0.001 vs. the control 
group. 
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1 patient using regular pain medication until the end of 
the 2nd week (p  ! 0.001). Ten control group patients were 
on regular or heavy pain medication during this period 
and continued using pain medication until 6 weeks post-
operatively ( table 3 ). The SIS was significantly better dur-
ing the postoperative period for patients treated with 
PLG (p  ! 0.001;  fig. 3 ). At the end of the follow-up period, 
a satisfying SIS was achieved in both groups. The control 
group improved 35% and the PLG-treated patients im-
proved 47% compared to the preoperative SIS measure-
ments, respectively. Six weeks postoperatively, the VAS 
scores of the control and treatment groups were 2.0  8 2.0 
and 1.1  8 0.3, respectively.
 Instability 
 The patient self-assessment score for instability showed 
no significant difference between both groups ( table 4 ). 
During the postoperative period, patients in the PLG-
treated group experienced slightly less shoulder instabil-
ity. However, the physician instability scores did not show 
differences between both groups (p = 0.13); the difference 
in the number of patients not experiencing instability 
was 1 patient less in the PLG group. In treated patients, 
the instability score was not significantly better com-
pared to control patients (p = 0.13).
 Activities of Daily Living 
 PLG-treated patients were able to perform more ac-
tivities listed on the ADL questionnaire 2 weeks postop-
eratively (p  ! 0.05) and they continued to perform better 
than the control patients, until 6 weeks postoperatively. 
Four weeks after surgery, PLG-treated patients were able 
to increase ADL performance and to sleep on the oper-
ated shoulder (p  ! 0.05). Patients in the treatment group 
were able to return to work earlier than did control pa-
tients.
 Range of Motion 
 Two weeks postoperatively, PLG-treated patients sig-
nificantly improved passive forward elevation (p  ! 0.001), 
external rotation, external rotation with arm at 90° ab-
duction, internal rotation, and cross body adduction 
compared to control patients. Four and 6 weeks after sur-
gery, PLG-treated patients still performed better than 
control patients, who tended to ‘catch up’ 3 months post-
operatively ( fig. 4–7 ).
 Discussion 
 Shoulder impingement is a common disorder and OSD 
has proven useful where conservative, non-operative 
therapies failed. The results of a well-performed acromio-
plasty are dependent on the time of postoperative reha-
bilitation. We have studied the outcome of OSD in com-
bination with the application of PLG at the end of the sur-
gical procedure. PLG is prepared from autologous whole 
blood donated before surgery and can be applied locally 
at the wound site to enhance soft tissue regeneration. The 
rationale to use PLG is the high contents of platelets, leu-
kocytes, and thrombin. PLG forms a source of growth fac-
tors, which are already present in vivo , at tissue wound 
sites  [15–17] . PLG has been used successfully to support 
wound healing  [18] , control bleeding  [6] , promote bone 
growth  [19] , and reduce infections  [20] . After a surgical 
incision, tissue repair begins with platelet plug formation, 
activation of the coagulation cascade, and platelet degran-
ulation. Platelet degranulation results in the release of 
0
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 Fig. 3. SIS score up to 6 weeks postoperatively of the control ( $ ) 
and PLG-treated patients ( ) ).  * p  ! 0.001 vs. the control group. 
Table 4. Self-evaluation instability score in patients treated with 
OSD
Control (n = 20) PLG (n = 20)
yes/no instable score yes/no instable score
Preoperatively 4/11 3.782.9 (0–9) 5/10 3.382.7 (0–8)
Postoperativley
1 week 4/11 2.982.6 (0–8) 3/12 1.882.1 (0–8)
2 weeks 3/12 1.681.6 (0–6) 2/13 1.480.6 (0–3)
4 weeks 3/12 2.181.9 (0–6) 2/13 1.780.9 (0–4)
6 weeks 2/13 2.082.0 (0–6) 1/14 1.180.3 (0–2)
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platelet growth factors, including TGF-  and -  , PDGF 
strain AB, fibroblast growth factor, and epidermal growth 
factor  [21] . During the different stages of wound healing, 
these specific platelet growth factors regulate processes 
involved in cell-cell and cell-matrix interactions required 
for wound healing. Various studies show the benefit of 
autologous PLG application. Platelet growth factors can 
work synergistically, promoting mitogenesis of mesen-
chymal stem cells at the wound site  [22–24] . In this study, 
patients treated with PLG had a more successful rehabili-
tation, with an earlier recovery of shoulder function. This 
was not solely due to less pain. The external/internal rota-
tion movement pattern was significantly better in treated 
patients, and this pattern is only weakly correlated to 
pain, as indicated by Holm et al.  [25] . Therefore, we pro-
pose that a high concentration of PDGF at the surgical 
wound site improves tissue healing, resulting in an im-
proved shoulder function with an earlier return of ADL. 
A drawback of this study is that patients were only fol-
lowed up for 3 months. Thus, it is not known at what point 
in time the non-treated patients were able to perform the 
same activities as the PLG-treated patients.
 In a wound treatment study by Crovetti et al.  [7] , a re-
duction in pain sensation was observed when PLG was 
applied, but they offered no explanation for these observa-
tions. In our study, the application of PLG resulted in less 
postoperative pain, decreased usage of pain medication, 
and a quicker recovery of shoulder function. Santavirta et 
al. [26] studied shoulder pain originating from the sub-
acromial bursa. They performed an immunohistochemi-
cal study in patients treated with OSD and demonstrated 
that immunoreactive sensory afferent fibers arise in the 
subacromial bursa. Interestingly, Sprott et al.  [27] report-
ed on pain reduction following acupuncture and mea-
sured a decrease in serotonin (5-HT) concentration in 
platelets from these patients and an increase in 5-HT lev-
els in plasma, suggesting normalization of plasma 5-HT 
levels due to the mobilization of platelet 5-HT. We also 
showed pain reduction after treatment with PLG, which 
might be the result of PLG application. Except for the   -
granules, platelets also contain dense granules, which 
hold large amounts of 5-HT  [28] . Since the platelet counts 
were almost sixfold higher in the PLG, 5-HT might have 
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been released at the wound site following platelet activa-
tion. Also, a chronic inflammatory reaction has been 
demonstrated  [29] , resulting in the activation of nocicep-
tors. These patients develop serious pain complaints  [30] . 
Blaine et al.  [31] proposed to use anti-inflammatory agents 
for the treatment of subacromial impingement ,  in order 
to reduce inflammation. In this regard, we postulate an 
additional effect of PLG when applied to inflammatory 
tissues, since we demonstrated that except for a high con-
centration of platelets, high concentrations of viable leu-
kocytes are present, in particular neutrophils and mono-
cytes  [10] . In addition, platelet growth factors initiate 
macrophage migration  [4] . Bielecki et al.  [32] demonstrat-
ed in an in vitro study an antibacterial effect of autologous 
PLG. Furthermore, Tang et al.  [33] demonstrated that 
platelets also have antimicrobial properties, as they con-
tain multiple antimicrobial peptides.
 Pain is an important symptom in patients with im-
pingement syndrome. Both treated and non-treated pa-
tients experienced the same pain sensation and therefore 
there was no statistical difference between the two groups 
before surgery. Postoperatively, the self-assessments 
showed that the ASES shoulder scores and range of mo-
tion were significantly improved in PLG-treated patients, 
experiencing less pain. The control group did not show 
the same clinical results as did the treated group, even 
after 3 months of rehabilitation. The impaired range of 
motion and increased sensation of shoulder pain could 
not be explained by baseline differences between the two 
groups or tears of the rotator cuff which did not occur. 
Furthermore, the earlier functional recovery of PLG-
treated patients was not hindered by surgery of the non-
dominant shoulder, as stated by Patel et al.  [34] , since we 
had an even distribution of dominant and non-dominant 
shoulders being operated on in our study. No side effects 
were noticed in patients who were treated with PLG. 
None of the treated patients demonstrated signs of in-
flammation as a result of their PLG injections when com-
pared to the non-treated patients (no differences in C-re-
active protein measurements between the two patient 
groups were seen, data not shown). Furthermore, PLG-
treated patients did not experience an increased inci-
dence of arthrofibrosis at postoperative evaluations. This 
is in accordance with results recently published by our 
group in patients in whom PLG was injected intracapsu-
larly after total knee replacement  [35] . Nonetheless, in 
these PLG-treated patients, a significantly decreased in-
cidence of arthrofibrosis was observed.
 In conclusion, this is the first prospective, random-
ized, blinded study using subacromial-applied PLG in 
OSD surgery. We demonstrated that the use of PLG in 
OSD is very effective for regaining early shoulder func-
tion with better control of postoperative pain. Future 
studies are warranted to elucidate the long-term effects of 
PLG application on shoulder function, and to clarify the 
role of platelets and leukocytes as anti-inflammatory 
agents of PLG.
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